PharmGen Science Inc
PharmGen Science, Inc. engages in the research and development, production, and sale of pharmaceutical products in South Korea. It provides prescription drugs, OTC drugs, diagnostic test kits, health and general foods, and cosmetics, as well as shampoo, conditioner, and hair oil products under the neomcell brand name. The company was formerly known as Wooridul Pharmaceutical Limited and changed i… Read more
PharmGen Science Inc (004720) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.008x
Based on the latest financial reports, PharmGen Science Inc (004720) has a cash flow conversion efficiency ratio of 0.008x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩1.91 Billion) by net assets (₩247.76 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
PharmGen Science Inc - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how PharmGen Science Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
PharmGen Science Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PharmGen Science Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kron Telekomunikasyon Hizmetleri AS
IS:KRONT
|
0.156x |
|
Shihlin Development Company Limited
TWO:5324
|
-0.058x |
|
Cuprum
SN:CUPRUM
|
0.041x |
|
Oncopeptides AB
ST:ONCO
|
-23.926x |
|
5paisa Capital Ltd
NSE:5PAISA
|
-0.100x |
|
BioNxt Solutions Inc.
OTCQB:BNXTF
|
0.244x |
|
Ditas Dogan Yedek Parca Imalat ve Teknik AS
IS:DITAS
|
-0.443x |
|
H&R GmbH & Co. KGaA
XETRA:2HRA
|
0.054x |
Annual Cash Flow Conversion Efficiency for PharmGen Science Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of PharmGen Science Inc from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩249.43 Billion | ₩2.38 Billion | 0.010x | -59.89% |
| 2023-12-31 | ₩228.21 Billion | ₩5.44 Billion | 0.024x | +483.79% |
| 2022-12-31 | ₩207.12 Billion | ₩-1.29 Billion | -0.006x | -110.13% |
| 2021-12-31 | ₩126.93 Billion | ₩7.78 Billion | 0.061x | +91.54% |
| 2020-12-31 | ₩83.57 Billion | ₩2.68 Billion | 0.032x | -28.64% |
| 2019-12-31 | ₩56.25 Billion | ₩2.52 Billion | 0.045x | -39.50% |
| 2018-12-31 | ₩56.85 Billion | ₩4.22 Billion | 0.074x | +106.01% |
| 2017-12-31 | ₩51.05 Billion | ₩1.84 Billion | 0.036x | -83.10% |
| 2016-12-31 | ₩36.41 Billion | ₩7.75 Billion | 0.213x | +68.55% |
| 2015-12-31 | ₩28.66 Billion | ₩3.62 Billion | 0.126x | +226.04% |
| 2014-12-31 | ₩20.12 Billion | ₩-2.02 Billion | -0.100x | +43.17% |
| 2013-12-31 | ₩23.83 Billion | ₩-4.20 Billion | -0.176x | -213.97% |
| 2011-12-31 | ₩18.69 Billion | ₩2.89 Billion | 0.155x | -- |